These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38860621)

  • 1. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
    McPherson S; Dyson JK; Jopson L; Masson S; Patel P; Anstee QM
    Aliment Pharmacol Ther; 2024 Jul; 60(2):267-273. PubMed ID: 38860621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.
    Anstee QM; Lawitz EJ; Alkhouri N; Wong VW; Romero-Gomez M; Okanoue T; Trauner M; Kersey K; Li G; Han L; Jia C; Wang L; Chen G; Subramanian GM; Myers RP; Djedjos CS; Kohli A; Bzowej N; Younes Z; Sarin S; Shiffman ML; Harrison SA; Afdhal NH; Goodman Z; Younossi ZM
    Hepatology; 2019 Nov; 70(5):1521-1530. PubMed ID: 31271665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.
    Ragazzo TG; Paranagua-Vezozzo D; Lima FR; de Campos Mazo DF; Pessoa MG; Oliveira CP; Alves VAF; Carrilho FJ
    Clinics (Sao Paulo); 2017 Oct; 72(9):516-525. PubMed ID: 29069254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
    Schmid P; Bregenzer A; Huber M; Rauch A; Jochum W; Müllhaupt B; Vernazza P; Opravil M; Weber R;
    PLoS One; 2015; 10(9):e0138838. PubMed ID: 26418061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAST and Agile-the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin.
    Taru MG; Tefas C; Neamti L; Minciuna I; Taru V; Maniu A; Rusu I; Petrushev B; Procopciuc LM; Leucuta DC; Procopet B; Ferri S; Lupsor-Platon M; Stefanescu H
    PLoS One; 2024; 19(5):e0303971. PubMed ID: 38781158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease.
    Lee DH; Sung SU; Lee YK; Lim IH; Jang H; Joo SK; Park JH; Chang MS; So YH; Kim W;
    Aliment Pharmacol Ther; 2022 Apr; 55(8):994-1007. PubMed ID: 35005800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-A prospective biopsy-controlled study.
    Bauer DJM; Nixdorf L; Dominik N; Schwarz M; Hofer BS; Hartl L; Semmler G; Jachs M; Simbrunner B; Jedamzik J; Mozayani B; Gensthaler L; Felsenreich DM; Trauner M; Langer FB; Mandorfer M; Prager G; Reiberger T
    Aliment Pharmacol Ther; 2024 Jul; 60(1):70-82. PubMed ID: 38693718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
    Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
    Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.